XOMA buys third biotech this month, as it swoops up Mural Oncology

XOMA Royalty is buying Mural Oncology for $2.03 per share, the companies said Wednesday morning. It's the third acquisition this month for XOMA, following deals for vaccine developer HilleVax and T ...